TY - JOUR
T1 - Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat ebv negative lymphoma
AU - Gerdemann, Ulrike
AU - Katari, Usha
AU - Christin, Anne S.
AU - Cruz, Conrad R.
AU - Tripic, Tamara
AU - Rousseau, Alexandra
AU - Gottschalk, Stephen M.
AU - Savoldo, Barbara
AU - Vera, Juan F.
AU - Heslop, Helen E.
AU - Brenner, Malcolm K.
AU - Bollard, Catherine M.
AU - Rooney, Cliona M.
AU - Leen, Ann M.
PY - 2011/12
Y1 - 2011/12
N2 - Although immunotherapy with Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes (CTLs) can treat EBV-associated Hodgkin and non-Hodgkin lymphoma (HL/NHL), more than 50% of such tumors are EBV negative. We now describe an approach that allows us to consistently generate, in a single line, CTLs that recognize a wide spectrum of nonviral tumor-associated antigens (TAAs) expressed by human HL/NHL, including Survivin, MAGE-A4, Synovial sarcoma X (SSX2), preferentially expressed antigen in melanoma (PRAME) and NY-ESO-1. We could generate these CTLs from nine of nine healthy donors and five of eight lymphoma patients, irrespective of human leukocyte antigen (HLA) type. We reactivated TAA-directed T cells ex vivo, by stimulation with dendritic cells (DCs) pulsed with overlapping peptide libraries spanning the chosen antigens in the presence of an optimized Th1-polarizing, prosurvival/proliferative and Treg inhibitory cytokine combination. The resultant lines of CD4 and CD8 , polycytokine- producing T cells are directed against a multiplicity of epitopes expressed on the selected TAAs, with cytolytic activity against autologous tumor cells. Infusion of such multispecific monocultures may extend the benefits of CTL therapy to treatment even of EBV negative HL and NHL.
AB - Although immunotherapy with Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes (CTLs) can treat EBV-associated Hodgkin and non-Hodgkin lymphoma (HL/NHL), more than 50% of such tumors are EBV negative. We now describe an approach that allows us to consistently generate, in a single line, CTLs that recognize a wide spectrum of nonviral tumor-associated antigens (TAAs) expressed by human HL/NHL, including Survivin, MAGE-A4, Synovial sarcoma X (SSX2), preferentially expressed antigen in melanoma (PRAME) and NY-ESO-1. We could generate these CTLs from nine of nine healthy donors and five of eight lymphoma patients, irrespective of human leukocyte antigen (HLA) type. We reactivated TAA-directed T cells ex vivo, by stimulation with dendritic cells (DCs) pulsed with overlapping peptide libraries spanning the chosen antigens in the presence of an optimized Th1-polarizing, prosurvival/proliferative and Treg inhibitory cytokine combination. The resultant lines of CD4 and CD8 , polycytokine- producing T cells are directed against a multiplicity of epitopes expressed on the selected TAAs, with cytolytic activity against autologous tumor cells. Infusion of such multispecific monocultures may extend the benefits of CTL therapy to treatment even of EBV negative HL and NHL.
UR - http://www.scopus.com/inward/record.url?scp=82955219544&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=82955219544&partnerID=8YFLogxK
U2 - 10.1038/mt.2011.167
DO - 10.1038/mt.2011.167
M3 - Article
C2 - 21915103
AN - SCOPUS:82955219544
VL - 19
SP - 2258
EP - 2268
JO - Molecular therapy : the journal of the American Society of Gene Therapy
JF - Molecular therapy : the journal of the American Society of Gene Therapy
SN - 1525-0016
IS - 12
ER -